{"id":63796,"date":"2025-08-12T11:01:22","date_gmt":"2025-08-12T11:01:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/63796\/"},"modified":"2025-08-12T11:01:22","modified_gmt":"2025-08-12T11:01:22","slug":"eli-lillys-orforglipron-data-is-not-disastrous-analyst-eli-lilly-nyselly","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/63796\/","title":{"rendered":"Eli Lilly’s Orforglipron Data Is Not Disastrous: Analyst – Eli Lilly (NYSE:LLY)"},"content":{"rendered":"

Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist<\/a>.<\/p>\n

For the primary endpoint, orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand, below Wall Street\u2019s expectations of around 15%<\/a>.<\/p>\n

Eli Lilly also released better-than-expected second-quarter earnings on Thursday and\u00a0raised 2025 guidance<\/a>.<\/p>\n

Bank of America (BofA) Securities said on Friday that the second quarter was strong. Mounjaro and Zepbound were meaningfully ahead of consensus.<\/p>\n

Also Read: Eli Lilly\u2019s Rare Weight Loss Data Miss Could Benefit Competitors<\/a><\/p>\n

However, analyst Tim Anderson said the orforglipron phase 3 data did not fall \u2018that short\u2019.<\/p>\n

He says if a patient weighs 300 pounds, this new data says they\u2019ll lose 33 pounds (11%), not the ~40lbs (13-14%) investors wanted. But 33 pounds is still quite meaningful for a GLP1 in a pill.<\/p>\n

The analyst said the results were not disastrous, but the stock reaction was overdone.<\/p>\n

With a Buy rating, BofA lowered the price forecast for Eli Lilly from $1,000 to $900<\/a>. The primary reason for investing in Eli Lilly is its strong and sustained growth compared to other pharmaceutical companies.<\/p>\n

Over the past five years, its earnings per share have grown about four times faster than the industry average. While the stock trades at a price-to-earnings ratio about 2.5 times higher than its peers, it still has the potential to keep beating expectations and raising guidance.<\/p>\n

Price Action: LLY stock is down 0.86% at $635.35 at the last check on Friday.<\/p>\n

Read Next<\/p>\n

Image: Shutterstock<\/p>\n

Stock Score Locked: Edge Members Only<\/p>\n

Benzinga Rankings give you vital metrics on any stock \u2013 anytime.<\/p>\n

Unlock Rankings<\/a>Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational…\n","protected":false},"author":2,"featured_media":63797,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[49,48,32267,32273,41002,41007,41005,41003,41004,41006,11669,84,392,11668,41008,41009,32278,41010],"class_list":{"0":"post-63796","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ca","9":"tag-canada","10":"tag-category-analyst-color","11":"tag-category-analyst-ratings","12":"tag-category-biotech","13":"tag-category-general","14":"tag-category-health-care","15":"tag-category-large-cap","16":"tag-category-news","17":"tag-category-price-target","18":"tag-cms-wordpress","19":"tag-health","20":"tag-healthcare","21":"tag-pageisbzpro-bz","22":"tag-symbol-lly","23":"tag-tag-expert-ideas","24":"tag-tag-stories-that-matter","25":"tag-tag-weight-loss"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/63796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=63796"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/63796\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/63797"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=63796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=63796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=63796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}